Announced details
sPGA 0/1 achievement rate at week 16: 71.4%, 69.2%
PASI 90 achievement rate at week 16: 61.3%, 51.9%
PASI 75 at week 4: 16.8% (zasocitinib group), 4.3% (placebo group)
More than 90% of patients who continued treatment at week 40 maintained their response at week 60
Incidence of all TEAEs through week 16: 62.1%
NCT06088043
NCT06108544
The information is not expected to have a material impact on the full-year consolidated earnings forecast for the fiscal year ending March 2026 (FY2025)
The company does not address Contract Value / Offering price.
American Academy of Dermatology 2026 Annual Meeting
ClinicalTrials.gov
IQVIA SOB Report
IQVIA
| Item | Details |
|---|---|
| Names of Products / Services Covered | Zasocitinib (TAK-279) |
| Applicable area | Moderate-to-severe plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis, Plaque vitiligo, Hidradenitis suppurativa |
| Registration number and expiry date | NCT06088043, NCT06108544 |
| Quantitative Effects | sPGA 0/1 achievement rate at week 16: 71.4%, 69.2%, PASI 90 achievement rate at week 16: 61.3%, 51.9%, PASI 75 at week 4: 16.8% (zasocitinib group), 4.3% (placebo group), More than 90% of patients who continued treatment at week 40 maintained their response at week 60, Incidence of all TEAEs through week 16: 62.1% |
| Impact on Business Performance | The information is not expected to have a material impact on the full-year consolidated earnings forecast for the fiscal year ending March 2026 (FY2025) |
| Source | American Academy of Dermatology 2026 Annual Meeting, ClinicalTrials.gov, IQVIA SOB Report, IQVIA |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.New data from two Phase 3 clinical trials were presented at the 2026 Annual Meeting of the American Academy of Dermatology (AAD). The company stated that zasocitinib demonstrated rapid and sustained improvement in skin symptoms with once-daily dosing and had a consistent safety profile with the Phase 2b trial.